Top Industry Leaders in the Pheochromocytoma Market
Latest Pheochromocytoma Companies Update:
Global Medical Technologies, Announced the commercial launch of its radiopharmaceutical Meta-Iobenzene-123I Injection (MIBG) for imaging and localization of pheochromocytomas and paragangliomas. This new option provides an alternative to existing imaging agents with potential advantages like lower radiation exposure and improved sensitivity.
Akcea Therapeutics Presented positive Phase 2 trial results for Tegsedimet (lomitapide), its oral medication for hypertriglyceridemia, showing potential benefits in managing metabolic complications associated with pheochromocytomas.
Bayer AG Partnered with the Pheochromocytoma and Paraganglioma Research Foundation (PPRF) to launch a patient registry, aiming to improve clinical research and treatment options for pheochromocytoma patients.
Karyopharm Therapeutics Received FDA orphan drug designation for Xpozio™ (selinexor) for the treatment of malignant pheochromocytomas and paragangliomas, offering a potential therapy option for advanced and aggressive cases.
List of Pheochromocytoma Key companies in the market
- Pfizer Inc. (US)
- Teva Pharmaceutical Company Limited (Israel)
- Zydus Cadila (India)
- Novartis AG (Switzerland)
- Curium Pharma (UK)
- Jubilant Cadista (US)
- AstraZeneca (UK)
- Mylan N.V. (US)
- Apotex Inc. (Canada)
- Reddy’s Laboratories Ltd (India)
- Lupin (India)
- Glenmark Pharmaceuticals Limited (India)